Patent · US Active

Zika virus vaccine

US11723967B2 · kind B2 · utility

3Cited by

1References

15Claims

0Family size

Assignees

CureVac SE · DE
Sanofi Pasteur, Inc. · US

Inventors

Benjamin PETSCH · Tübingen, DE
Edith JASNY · Stuttgart, DE
Yves Girerd-Chambaz · Messimy, FR

Key dates

Filing date	Feb 17, 2017
Grant date	Aug 15, 2023
Priority date	—
Expiry date	Dec 17, 2040

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or prophylaxis of an infection with Zika virus or a disorder related to such an infection. In particular, the present invention concerns a Zika virus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.